While potential Trump tariffs spark investor anxiety, a far more critical risk is unfolding in Asia. Are you prepared?

We take a look at 4 Pharma & Biotech companies whose share prices rallied in October on the back of positive announcements.

There may not be industry-wide reporting just yet but transparency around returns and fees are finally coming through in ...

Whilst Zoom has made communicating with companies far more efficient, at NAOS we still believe that nothing beats a ...

Australian investors have long favoured traditional assets, like stocks, bonds, and brick-and-mortar property.

Despite pressure on consumer spending, consumers prioritise trusted brands for their health-related needs and Haleon is a ...

And why Lazard Asset Management's June-Yon Kim believes investors can expect improving earnings growth from Japanese ...

The Fed’s November rate cut, though widely expected, sets a cautious tone as policymakers navigate a complex landscape under ...

Koda Capital's Chief Economist Brigette Leckie explains how moves in the global economy shape decisions for investors and ...

Sometimes, the short sellers get it wrong. So, are there any opportunities among the most shorted ASX stocks? Find out in ...

Platinum Asset Management's biotech specialist Dr Bianca Ogden outlines the major opportunities she is seeing in the sector.

Trump intends to unlock vast O&G reserves in the US and drive prices lower by flooding the economy with new supply. Time to ...